Mirum Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 29, 2025, details the results of Mirum Pharmaceuticals, Inc.'s 2025 Annual Meeting of Stockholders. The record date for the meeting was April 3, 2025, with 49,454,336 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on three primary proposals at the Annual Meeting:
- Proposal 1: Election of Directors
- Laura Brege: Elected with 17,968,766 votes for and 18,167,097 votes withheld.
- Michael Grey: Elected with 30,777,470 votes for and 5,358,393 votes withheld.
- Christopher Peetz: Elected with 35,980,278 votes for and 155,585 votes withheld.
- All three directors were elected to serve as Class III directors until the 2028 annual meeting.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Results: 43,115,134 votes for, 19,188 votes against, and 19,376 abstentions.
- Proposal 3: Advisory Vote on Executive Compensation
- Stockholders approved the compensation of named executive officers on an advisory basis.
- Results: 34,671,826 votes for, 1,455,143 votes against, and 8,894 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the significant number of votes withheld for director Laura Brege (18,167,097) compared to votes cast for her (17,968,766), indicating substantial shareholder dissent despite her election.
- Confirm the total number of broker non-votes (7,017,835) which impacted the voting dynamics for all proposals.
- Review the full Proxy Statement referenced in the filing for detailed executive compensation data and director biographies.
- Note that the company is an emerging growth company, which may affect financial reporting requirements.